Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Col... ( SAN DIEGO and CAMBRIDGE Mass. Apr...)

Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration

Date:4/28/2008

SAN DIEGO and CAMBRIDGE, Mass., April 28 /PRNewswire/ -- ChemDiv, Inc., a global CRO for drug discovery & development, and Syndexa Pharmaceuticals Corporation, a biopharmaceutical company developing first-in-class drugs for the treatment of metabolic diseases, have announced today the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outSource(TM) platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global CRO delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource(TM) a full service drug discovery offering encompassing synthetic chemistry; medicina
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
7. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
8. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
9. MacroChem Acquires Virium Pharmaceuticals
10. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
11. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference

Post Your Comments:

Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Col...( SAN DIEGO and CAMBRIDGE Mass. Apr...)